Share this post on:

product name Tenovin-6


Description: Tenovin-6 is an analog of tenovin-1 with more water-soluble and it inhibits the protein deacetylase activities of SIRT1, SIRT2 and SIRT3 with IC50 value of 21 μM, 10 μM, and 67 μM, respectively. It has been identified that　the cytotoxic effects of　tenovin-6 may occur through the dysregulation of autophagy rather　than induction of apoptosis in chronic lymphocytic leukemia cells. Sir2p homologs could be targets　for tenovin-6 in mammalian cells. Tenovin-6 decreases purified human SirT1 peptide deacetylase activity in vitro with an IC50 of 21 mM and human SirT2 activity with an IC50 of 10 mM.

Reference: Cancer Cell. 2008 May;13(5):454-63.



Molecular Weight (MW)

454.63
Formula

C25H34N4O2S
CAS No.

1011557-82-6
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO: 98 mg/mL (215.55 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: <1 mg/mL (slightly soluble or insoluble)
Solubility (In vivo)

 

other peoduct :

General Tenovin-6 is a more water-soluble analog of tenovin-1. Tenovin-6 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 in vitro with IC50 of 21 μM, 10 μM, and 67 μM, respectively.
Animal model ARN8 melanoma cells were injected into the flank of SCID mice and allowed to develop into tumors. 
Formulation  
Dosages  50 mg/kg
Administration  i.p.
Reference [1] Lain S, et al. Cancer Cell, 2008, 13(5), 454-463.

USP7/USP49 inhibitor